SCHEMBL1355876

SCHEMBL1355876

CS(=O)(=O)N(CCN1CCCCC1)c1cc[c]cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.43
AURKA O14965 3/20 0.40
CDK1 P06493 3/20 0.40
CCNB1 P14635 3/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2D6 P10635 1/20 0.37
MAPK1 P28482 1/20 0.37
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MMP3 P08254 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355593 0.99 SIGMAR1 (0.41) SIGMAR1AURKACDK1CCNB1CYP3A4
SCHEMBL1356127 0.86 AURKA (0.46) AURKACDK1CCNB1CYP3A4CYP2C9
SCHEMBL4931400 0.84 SIGMAR1 (0.48) SIGMAR1MEN1KMT2ACYP2D6MAPK1
SCHEMBL1353734 0.78 ALDH1A1 (0.57) MEN1KMT2AMAPK1GAAMAPT
SCHEMBL3838440 0.77 SIGMAR1 (0.40) SIGMAR1AURKACDK1CCNB1CYP2D6
SCHEMBL11710790 0.77 LTA4H (0.50) KMT2ACYP2D6MAPK1ALDH1A1HRH3
SCHEMBL11713568 0.77 LTA4H (0.50) KMT2ACYP2D6MAPK1ALDH1A1HRH3
SCHEMBL11710785 0.75 LTA4H (0.51) SIGMAR1KMT2AGAAMAPTSMN1; SMN2
SCHEMBL6555097 0.75 ALDH1A1 (0.50) SIGMAR1MEN1KMT2ACYP2D6MAPK1
SCHEMBL1355116 0.73 MMP2 (0.37) AURKACDK1CCNB1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 SIGMAR1 2913/4885AURKA 9/4885CDK1 3/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 SIGMAR1 2913/4885AURKA 9/4885CDK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.